Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam ED50 and ED90 for Preoperative Sedation in Children Undergoing Tonsillectomy/Adenoidectomy
ChiCTR2600128817Phase 4Not yet recruiting
- Sponsor
- Children's Hospital of Chongqing Medical University
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam in Tonsillar hyperplasia, adenoidal hypertrophy and preoperative anxiety (4 cohorts), sponsored by Children's Hospital of Chongqing Medical University. Primary endpoints: Parent–child separation score (primary), Effective dose (ED50) of remimazolam for preoperative sedation and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
Tonsillar hyperplasiaadenoidal hypertrophypreoperative anxiety
Beyond the preview
Go deeper on ChiCTR2600128817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128817.